65th ASH Annual Meeting & Exposition: 622. Lymphomas: Translational

Symposia: Lymphomas: Translational–Non-Genetic Oral and Poster Abstracts
Poster

Research, Fundamental Science, Hodgkin lymphoma, Biological therapies, Antibody Therapy, artificial intelligence (AI), Translational Research, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Non-Biological therapies, assays, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, bioinformatics, Diversity, Equity, and Inclusion (DEI) , T Cell lymphoma, Checkpoint Inhibitor, Diseases, indolent lymphoma, immune mechanism, aggressive lymphoma, Therapies, Immunotherapy, immunology, Lymphoid Malignancies, computational biology, Monoclonal Antibody Therapy, Biological Processes, emerging technologies, molecular biology, Technology and Procedures, gene editing, multi-systemic interactions, profiling, Study Population, Human, pathogenesis, imaging, Animal model, Minimal Residual Disease , machine learning, molecular testing, omics technologies, Pathology, Serologic Tests

Halls G-H (San Diego Convention Center)

This Poster Session Includes Diverse Basic/Translational Research Findings that Offer New Insights in the Pathogenesis, Diagnosis, Prognosis, and Therapeutic Targeting of Lymphoid Malignancies.

1639

18F-FDG PET/CT Imaging Biomarkers for CAR-T Cell Therapy Outcomes in Large-B-Cell Lymphoma

Doris Leithner, MD¹^*, Jessica R. Flynn, MS²^*, Sean M. Devlin, PhD³^*, Audrey Mauguen, PhD⁴^*, Teng Fei, PhD⁵^*, Shang Zeng⁶^*, Brandon S. Imber, MD, MA⁷, Harper Hubbeling, MD⁸, Marius Mayerhoefer⁶^*, Efrat Luttwak, MD⁹, Magdalena Corona, MD¹⁰^*, Parastoo Bahrami Dahi, MD¹¹^*, Alejandro Luna De Abia⁶^*, Ivan Landego, MD¹²^*, Richard J. Lin, MD, PhD¹⁰, Maria Lia Palomba, MD¹³, Michael Scordo¹⁰, Ana Alarcon Tomas, MD⁸^*, Gilles Salles, MD, PhD⁹, Daniel Lafontaine⁶^*, Laure Michaud⁸^*, Gunjan L. Shah⁸, Miguel-Angel Perales, MD¹⁴, Heiko Schoder, MD¹⁵^* and Roni Shouval, MD, PhD¹⁰

¹Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York
³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Memorial Sloan Kettering Cancer Center, New York
⁷Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
⁸Memorial Sloan Kettering Cancer Center, New York, NY
⁹Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹¹Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹²Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
¹⁴Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York

1640

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

David M Foureau, PhD¹, Hamid Ehsan, MD, MBBS, MS, BS², Fei Guo, PhD¹^*, Tahj Jones¹^*, Ryan W Jacobs, MD³, Bei Hu, MD⁴, Tamara K. Moyo, MD⁵^*, Yifan Pang, MD⁶, Steven I. Park, MD⁷, Lawrence J. Druhan, PhD⁸, Ariel Bell, MPH⁹^* and Nilanjan Ghosh, MD³

¹Levine Cancer Institute, Atrium Health, Charlotte, NC
²Atrium health / Levine Cancer Institute, Waxhaw, NC
³Atrium Health Levine Cancer Institute, Charlotte, NC
⁴Department of Hematologic Oncology and Blood Disorders, Atrium Health / Levine Cancer Institute, Charlotte, NC
⁵Atrium Health / Levine Cancer Institute, Charlotte, NC
⁶Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
⁷Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
⁸Hematology Oncology Translational Research Laboratory, Atrium Health Levine Cancer Institute, Charlotte, NC
⁹Atrium Health / Levine Cancer Institute, Charlotte

1641

CDK9 Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma (MCL)

Carly Roleder¹^*, Edward C. Dominguez, PhD¹^*, Andrew Chen¹^*, Brian J. Ball, MD², Olga Danilova, MD, PhD¹^* and Alexey Danilov, MD³

¹City of Hope, Duarte, CA
²Hematology/HCT, City of Hope National Medical Center, Duarte, CA
³Department of Hematology and HCT, City of Hope National Medical Center, La Canada Flintridge, CA

1642

Macrophages Play a Key Role in Controlling Tumor Growth and Response to Immunotherapy in Primary Central Nervous System Lymphoma

Carlota Pages-Geli¹^*, Daniel Medina, MSc, BSc²^*, Cristina Hernandez¹^*, Patricia Fernandez¹^*, Gemma Pujadas, PhD²^*, Francesc Bosch, MD, PhD^2,3 and Marta Crespo, PhD¹^*

¹Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
²Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
³Hematology Department, Vall d'Hebron University Hospital, Barcelona, Spain

1643

IRF4 Rewires Tumor Metabolism with Functional Implications on the Immune Microenvironment in Lymphoma

Patrizia Mondello, MD, PhD, MSc¹, Vaishali Bhardwaj, PhD¹, Kerstin Wenzl, PhD¹^*, Joshua Olson²^*, Christine Hachfeld¹^*, Prithviraj Mukherjee¹^*, Xinyi Tang¹^*, Joseph P. Novak¹^*, Zhi-Zhang Yang¹^*, Megan Weivoda, PhD¹, Nicholas Graham³^*, Laura Pasqualucci, MD⁴^*, Mark Shlomchik⁵^*, Anne J. Novak, PhD¹ and Stephen M Ansell, MD, PhD¹

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Division of Radiology-Diagnostic, Mayo Clinic, Rochester, MN
³Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA
⁴Institute for Cancer Genetics, Columbia University, New York, NY
⁵Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

1644

Paulina Nierychlewska, MD¹^*, Maria Rosaria Sapienza, MD²^*, Alessandro Davini¹^*, Eugenia Montanari, MD^3,4^*, Anna Vanazzi, MD¹^*, Simonetta Viviani, MD¹^*, Valentina Tabanelli²^*, Roberto Massimo Lemoli, MD^5,6^*, Corrado Tarella¹^*, Stefano Pileri² and Enrico Derenzini, MD^1,7^*

¹Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy
²Haematopathology Division, IEO European Institute of Oncology IRCCS, Milan, Italy
³IRCCS Ospedale Policlinico San Martino, Genoa, Italy
⁴Clinic of Hematology, University of Genoa, Genoa, Italy
⁵Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
⁶Clinica Ematologica, Dipartimento di Oncologia e Ematologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
⁷Department of Health Sciences, University of Milan, Milan, Italy

1645

Measuring CD8-Positive T-Cells in the Tumor Microenvironment in Classical Hodgkin Lymphoma Using Multiplex Immunofluorescence Staining and Image Analysis: A Possible Prognostic Factor

Hiromichi Takahashi, MD, PhD¹^*, Shun Ito, MD¹^*, Yoko Nakanishi, PhD²^*, Katsuhiro Miura, MD, PhD¹^*, Masaru Nakagawa, MD, PhD¹^*, Shimon Otake, MD, PhD¹^*, Takashi Hamada, MD, PhD¹^*, Takashi Koike, MD¹^*, Kazuhide Iizuka, MD, PhD^1,3^*, Yuichi Takeuchi, MD¹^*, Kazuya Kurihara, MD¹^*, Toshihide Endo, MD¹^*, Hironao Nukariya, MD¹^*, Yoshihiro Hatta, MD¹, Shinobu Masuda, MD, PhD²^* and Hideki Nakamura, MD, PhD¹^*

¹Department of Medicine Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan
²Department of Pathology and Microbiology Division of Oncologic Pathology, Nihon University School of Medicine, Tokyo, Japan
³Department of Pathology and Microbiology Division of Laboratory Medicine, Nihon University School of Medicine, Tokyo, Japan

1646

Preclinical Evaluation of the Efficacy of Human Sirpα Antibodies for B-Cell Lymphoma Immunotherapy in Humanized Mouse Models

Yasuyuki Saito, MD, DPhil¹^*, Afroj Tania²^*, Satomi Komori²^*, Tomoko Takai²^*, Okechi S Oduori²^*, Takenori Kotani³^*, Yohei Funakoshi, MD⁴^*, Yoji Murata³^*, Kimikazu Yakushijin, MD, PhD⁴, Hiroshi Matsuoka, MD⁵^*, Hironobu Minami, MD⁴^*, Markus G. Manz, MD^6,7 and Takashi Matozaki²^*

¹Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, HYO, Japan
²Division of Biosignal Regulation, Kobe University Graduate School of Medicine, Kobe, Japan
³Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, Kobe, Japan
⁴Department of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan
⁵Division of Bioresource Research and Development, Kobe University Hospital, Kobe, Japan
⁶Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
⁷Comprehensive Cancer Center Zurich, Zurich, Switzerland

1647

Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas

Nermin Kady¹^*, Chenguang Wang¹^*, Ashley Wolfe¹^*, Ira Maine¹^*, Suhaib Abdelrahman¹^*, Carlos A. Murga-Zamalloa, MD² and Ryan A. Wilcox, MD³

¹University of Michigan, Ann Arbor, MI
²University of Illinois Chicago, Chicago, IL
³Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, MI

1648

Xpo-1 Antagonism Transcriptionally Reprograms and Is a Therapeutic Vulnerability in GATA-3 Driven T-Cell Lymphomas

Chenguang Wang¹^*, Nermin Kady¹^*, Ashley Wolfe¹^*, Ira Maine¹^*, Suhaib Abdelrahman¹^*, Vanessa Perez Silos²^*, Carlos A. Murga-Zamalloa, MD³ and Ryan A. Wilcox, MD⁴

¹University of Michigan, Ann Arbor, MI
²Department of Pathology, University of Illinois Chicago, Chicago, IL
³University of Illinois Chicago, Chicago, IL
⁴Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, MI

1649

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, MD^1,2^*, Ying Yu^1,2^*, Yanshan Huang^1,2^*, Rui Cui, MD³^*, Jingwen Sun, MD^1,2^*, Rui Lyu^1,2^*, Tingyu Wang^1,2^*, Wenjie Xiong^1,2^*, Yuting Yan^1,2^*, Qi Wang^1,2^*, Wei Liu, MD^1,2^*, Gang An^1,2^*, Weiwei Sui^1,2^*, Yan Xu, PhD^1,2^*, Wenyang Huang^1,2^*, Dehui Zou^2,4^*, Lugui Qiu^1,2 and Shuhua Yi^1,2^*

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²Tianjin Institutes of Health Science, Tianjin, China
³Department of hematology, Tianjin First center hospital, Tianjin, China
⁴Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

1650

Pathobiology and Targeting of CD38 in Cutaneous T-Cell Lymphoma

Colleen Isabelle¹, Amy Boles¹^*, Kathleen McConnell¹^*, Robyn Keller¹^*, Lara Cheslow¹^*, Jonathan Xu²^*, Scott Waldman, MD PhD¹^*, Nitin Chakravarti, PhD³, Pierluigi Porcu, MD^4,5, Neda Nikbakht, MD⁶^* and Anjali Mishra, PhD⁷

¹Thomas Jefferson University, Philadelphia, PA
²Department of Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA
³Sidney Kimmel Cancer Center At Jefferson, Philadelphia, PA
⁴Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
⁵Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA
⁶Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA
⁷Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Thomas Jefferson University Sydney Kimmel Cancer Center, Philadelphia, PA

1651

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, MD¹, Thomas Ollila, MD¹, Ari Pelcovits, MD², Anna Dorota Chorzalska, PhD³^*, John Morgan, PhD³^*, Jessica McMahon, BSN⁴^*, Stephen Donnelly, BS⁵^*, Scott F. Huntington, MD, MPH, MSc⁶, Matthew Matasar, MD, MS⁷, John L. Reagan, MD⁸, Charles Milrod, MD⁹ and Patrycja M. Dubielecka, PhD³

¹Brown University, Providence, RI
²Lifespan Cancer Institute, Legoretta Cancer Center of Brown University, Providence, RI
³Signal Transduction Lab, Rhode Island Hospital, Providence, RI
⁴Lifespan Cancer Institute, Providence, RI
⁵Lifespan Oncology Clinical Research, Rhode Island Hospital, Providence, RI
⁶Yale University, New Haven, CT
⁷Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ
⁸Legorreta Cancer Center of Brown University, Providence, RI
⁹Rhode Island Hospital, Providence, RI

1652

Lactate-Mediated Histone H3K9 Lactylation Facilitates Tumorigenesis of T-Cell Lymphoma Via Activation of SFXN1 Expression

Zhuoya Yu¹^*, Xiangxiang Zhou²^*, Yiqing Cai¹^*, Tiange Lu¹^*, Mengfei Ding¹^* and Xin Wang, MD, PhD^1,3

¹Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
³Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China

1653

No Discernable Dysfunction of Peripheral T-Cells and NK-Cells Despite Distinct Phenotypes in MYC Rearranged Versus Non Rearranged B-Cell Lymphoma Patients

A. Vera de Jonge, MD^1,2^*, Carolien Duetz, MD^1,2^*, Wassilis S.C Bruins, MD, MSc^1,2^*, Charlotte L.B.M. Korst^1,2^*, Rosa Rentenaar^1,2^*, Meliha Cosovic^1,2^*, Merve Eken^1,2^*, Inoka Twickler^1,2^*, Marcel Nijland, MD PhD³^*, Marjolein Van Der Poel, MD, PhD⁴^*, Koen de Heer, MD⁵^*, Clara Klerk, MD PhD⁶^*, Leonie Strobbe, MD⁷^*, Margriet Oosterveld, MD⁸^*, Rinske Boersma, MD⁹^*, Harry R. Koene, MD PhD¹⁰^*, Erik van Werkhoven, MSc^11,12^*, Martine E.D. Chamuleau, MD PhD^1,2 and Tuna Mutis, MD PhD^1,2^*

¹Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
²Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
³Department of Hematology, University Medical Center Groningen, Groningen, Netherlands
⁴Maastricht University Medical Center, Maastricht, Netherlands
⁵Department of Internal Medicine, Flevoziekenhuis, Almere, Netherlands
⁶Department of Internal Medicine, Dijklanderziekenhuis, Hoorn, NLD
⁷Department of Internal Medicine, Gelreziekenhuizen, Zutphen, Netherlands
⁸Canisius-Wilhelmina Hospital, Nijmegen, NLD
⁹Department of Internal Medicine, Amphia Ziekenhuis, Breda, Netherlands
¹⁰St. Antonius Hospital, Nieuwegein, NLD
¹¹Department of Hematology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands
¹²HOVON foundation, Rotterdam, Netherlands

1654

Multiple Doses of Cnty-101, an iPSC-Derived Allogeneic CD19 Targeting CAR-NK Product, Are Safe and Result in Tumor Microenvironment Changes Associated with Response: A Case Study

Indu Ramachandran¹^*, Sarah Rothman, PhD¹^*, Mariano Clausi, PhD¹^*, Kile Mcfadden¹^*, Brenda Salantes, PhD¹^*, Gloria Jih, PhD¹^*, Thomas Brigman¹^*, Sam Kelly¹^*, Matthew S Hall¹^*, Stephanie Yee¹^*, Iphigenia Koumenis¹^*, Poulomee Das¹^*, Jordan Briggs²^*, Tori Braun²^*, Ying Yuan³^*, Elizabeth Devlin¹^*, Adrienne Farid, PhD¹^*, Nikolaus S. Trede, MD, PhD¹, Tamara K. Moyo, MD⁴^*, Tahir Latif, MD⁵ and Krish Patel, MD²

¹Century Therapeutics, Philadelphia, PA
²Swedish Cancer Institute, Seattle, WA
³MD Anderson Cancer Center, Houston, TX
⁴Atrium Health / Levine Cancer Institute, Charlotte, NC
⁵University of Cincinnati Medical Center, Cincinnati, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

622.P1.47 622. Lymphomas: Translational – Non-Genetic: Poster I